Foresite Capital Management II, LLC - Q2 2021 holdings

$372 Million is the total value of Foresite Capital Management II, LLC's 4 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .

 Value Shares↓ Weighting
TXG Sell10x Genomics, Inc.$343,376,000
-15.8%
1,753,528
-22.2%
92.37%
-1.5%
NVAX  Novavax, Inc.$14,304,000
+17.1%
67,3730.0%3.85%
+37.0%
EPZM  Epizyme, Inc.$8,310,000
-4.6%
1,000,0020.0%2.24%
+11.6%
XLRN  Acceleron Pharma Inc.$5,758,000
-7.5%
45,8840.0%1.55%
+8.3%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Epizyme, Inc.29Q4 202111.9%
Acceleron Pharma Inc.24Q3 20214.8%
Aerie Pharmaceuticals, Inc.22Q1 202040.3%
10x Genomics, Inc.17Q3 2023100.0%
Aimmune Therapeutics, Inc.17Q3 201941.0%
Alder BioPharmaceuticals, Inc.16Q3 201912.6%
Zafgen, Inc.12Q3 201733.5%
BioDelivery Sciences International, Inc.12Q1 20193.2%
Insmed Incorporated11Q1 202013.8%
Adaptimmune Therapeutics PLC9Q4 201811.3%

View Foresite Capital Management II, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2023-11-13
13F-HR2023-08-11
13F-HR2023-05-12
13F-HR2023-02-13
13F-HR2022-11-14
13F-HR2022-08-12
13F-HR2022-05-13
13F-HR2022-02-11
13F-HR2021-11-12
13F-HR2021-08-16

View Foresite Capital Management II, LLC's complete filings history.

Compare quarters

Export Foresite Capital Management II, LLC's holdings